BHC(SH:600721) Xin Lang Cai Jing·2025-12-19 02:08Core Viewpoint - Baihua Pharmaceutical has seen a stock price increase of 5.04% on December 19, reaching 11.04 CNY per share, with a total market capitalization of 4.245 billion CNY, indicating a cumulative increase of 4.79% over three consecutive days [1] Company Overview - Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. is located in Urumqi, Xinjiang, and was established on June 21, 1996, with its listing date on June 26, 1996 [1] - The company specializes in early drug discovery and screening, drug CMC development, clinical trials, registration applications, BE/PK, biological sample analysis, pharmaceutical testing services, clinical SMO and data services, MAH services, and API and intermediate production supply, providing a comprehensive one-stop outsourcing and technology transfer service [1] - The revenue composition of the company includes: clinical trials (49.39%), pharmaceutical R&D and consistency evaluation (42.67%), leasing and property services (6.69%), other income (0.94%), and other (supplementary) (0.31%) [1] Fund Holdings - According to data, Huatai-PB Fund has a significant holding in Baihua Pharmaceutical, with the Huatai-PB CSI 2000 Index Enhanced A Fund (019923) holding 1.0891 million shares, representing 0.63% of the fund's net value, ranking as the fifth-largest holding [2] - The fund has realized a floating profit of approximately 577,200 CNY today, with a floating profit of 522,800 CNY during the three-day increase [2] - The Huatai-PB CSI 2000 Index Enhanced A Fund was established on January 12, 2024, with a current scale of 312 million CNY, and has achieved a year-to-date return of 46.88%, ranking 528 out of 4,197 in its category [2] Fund Manager Performance - The fund managers of Huatai-PB CSI 2000 Index Enhanced A include Sheng Hao, Lei Wenyuan, and Kong Lingye [3] - Sheng Hao has a tenure of 10 years and 71 days, managing assets totaling 4.417 billion CNY, with the best fund return of 128.74% and the worst return of -29.48% during his tenure [3] - Lei Wenyuan and Kong Lingye both have a tenure of 3 years and 138 days, managing assets of 2.345 billion CNY and 2.577 billion CNY respectively, with the best return of 71.86% and the worst return of 0.74% for Lei Wenyuan, and a best return of 71.86% and worst return of -0.68% for Kong Lingye [3]